News & Updates
Showing Cardiology articles
Showing
Show Multimedia Only

Empagliflozin lowers mortality, cardiorenal events even in COPD presence
28 Mar 2022
byJairia Dela Cruz
Among patients with type 2 diabetes mellitus and cardiovascular disease, those with concomitant chronic obstructive pulmonary disease (COPD) are at higher risk of mortality and adverse cardiorenal outcomes, including heart failure, according to post hoc analyses of the EMPA-REG OUTCOME trial. However, these outcomes can be prevented with empagliflozin treatment, regardless of the presence of COPD.
28 Mar 2022







